相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro
Johanna Weiss et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
Shirin Bruderer et al.
AAPS JOURNAL (2012)
Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment
Patricia Sidharta et al.
CHEST (2012)
Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial
Lewis Rubin et al.
CHEST (2012)
Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment
Patricia Sidharta et al.
CHEST (2012)
The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist
Martin H. Bolli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
John Gatfield et al.
PLOS ONE (2012)
Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans
Shirin Bruderer et al.
XENOBIOTICA (2012)
Macitentan: entry-into-humans study with a new endothelin receptor antagonist
Patricia N. Sidharta et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Seongwook Jeong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan
Oliver Kummer et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan
Duncan B. Richards et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Endothelin: 20 years from discovery to therapy
Matthias Barton et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2008)
Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Marc Iglarz et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects:: pharmacokinetic and pharmacodynamic effects
P Chaikin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole
PLM van Giersbergen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin:: comparison of the effect in healthy volunteers and in HIV-infected patients
S Grub et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Endothelin system: The double-edged sword in health and disease
RM Kedzierski et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Effects of the antifungal agents on oxidative drug metabolism - Clinical relevance
K Venkatakrishnan et al.
CLINICAL PHARMACOKINETICS (2000)
分享论文
